Patents Represented by Attorney, Agent or Law Firm Todd A. Lorenz
-
Patent number: 7812124Abstract: A method of diagnosing cancer comprising the identification of neoplastic molecular markers is disclosed. Tumor-related or neoplastic molecular markers are identified from samples taken from a subject and the molecular profile of those markers is determined. Based upon the neoplastic molecular marker profile of the subject, the tumor sub-type is ascertained and an appropriate treatment protocols initiated.Type: GrantFiled: November 30, 2006Date of Patent: October 12, 2010Inventor: Kaia Palm
-
Patent number: 7671026Abstract: The methods and compositions relate to treatment of disorders of the bladder. In particular, the methods provide for treatment of interstitial cystitis and related disorders. The methods further comprise treatment to affect various manifestations associated with interstitial cystitis, including, reducing histamine release, modulating Substance P expression, modulating nerve growth factor expression, modulating levels of various cytokines, and maintaining integrity of the urine/blood barrier.Type: GrantFiled: November 17, 2003Date of Patent: March 2, 2010Assignee: Sangstat Medical CorporationInventors: Timothy Fong, Alexis E. Te
-
Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation
Patent number: 6696545Abstract: Novel oligopeptides comprising a sequence derived by a computer program are provided for use in inhibiting cytotoxic activity of lymphocytic cells, inhibiting the production of inflammatory cytokines and inflammatory responses associated with those cytokines, inhibiting the activity of heme-containing enzymes and delaying the onset of an autoimmune disease in a mammal at risk of developing the disease. By combining the subject compositions with mixtures of cells comprising lymphocytic cells and cells which would otherwise activate the lymphocytic cells, lysis of the target cells can be substantially inhibited. The oligopeptides may be joined to a wide variety of other groups or compounds for varying the activity of the subject compositions.Type: GrantFiled: February 23, 1998Date of Patent: February 24, 2004Assignee: Sangstat Medical CorporationInventors: Roland Buelow, Gèrard Grassy, Bernard Calas -
Patent number: 6590091Abstract: Methods and compositions are provided for detecting nucleic acid sequences. In particular, pairs of probes are employed, where the pair defines a substantially contiguous sequence on a target nucleic acid. Each of the pairs has a side chain which forms a stem of the two side chains which non-covalently binds and is capable of forming a cross-link upon activation, when the probes and sample nucleic acid are base paired. Cross-linking of the stems when unbound to complementary DNA is inhibited. Each of the nucleic acids is initially present as single stranded nucleic acid to allow for base pairing, so that the probes bind to homologous target nucleic acid. The assay mixture is activated to provide cross-linking, the double stranded nucleic acid melted, and the process of base pairing, activation and melting repeated, a sufficient number of cycles, to provide a detectable amount of cross-linked probes.Type: GrantFiled: January 9, 2001Date of Patent: July 8, 2003Assignee: NaxcorInventors: David Albagli, Reuel VanAtta, Michael Wood
-
Patent number: 6503747Abstract: Recombinant nucleic acids comprising region(s) of Listeria monocytogenes genome that are unique to an individual serotype and genomic cluster are provided. Also provided are oligonucleotide probes and primers derived from the recombinant nucleic acid sequences and methods for their use in the detection and identification serovar 4 and genomic cluster IIB strains.Type: GrantFiled: July 14, 1998Date of Patent: January 7, 2003Assignee: University of HawaiiInventors: Sophia Kathariou, Xiang-He Lei
-
Patent number: 6495676Abstract: Methods and compositions are provided for detecting nucleic acid sequences. Probes comprising a crosslinking agent are combined with a sample which may comprise a target sequence which is complementary to the probe. Hybridization is allowed to occur between complementary sequences. The crosslinking agent is activated. Covalent bonds are formed between the probe and the target sequence if they are hybridized to one another. The crosslinked nucleic acids can then be detected to indicate the presence of the target sequence. Also provided are kits comprising reagents.Type: GrantFiled: September 3, 1999Date of Patent: December 17, 2002Assignee: NaxcorInventors: Michael L. Wood, David Albagli, Reuel B. Van Atta, Douglas Y. Thien, Peter C. Cheng, Bingfang Huan
-
Patent number: 6420523Abstract: The present invention provides compositions of matter comprising a polypeptide expressed from insect cells harboring a baculovirus vector the encodes the polypeptide, wherein the polypeptide comprises amino acid sequences derived from the p42 fragment of the Plasmodium falciparum gp 195 protein or derivatives thereof. Such compositions of matter find use for example for inducing the production of anti-p42 antibodies both in vivo and in vitro.Type: GrantFiled: February 14, 1994Date of Patent: July 16, 2002Assignee: University of HawaiiInventors: Sandra Chang, George S. N. Hui, Philip J. Barr, Helen Gibson
-
Patent number: 6403302Abstract: Improved oligonucleotides and processes for their use for specific recognition of a target sequence in double-stranded nucleic acid through the formation of an alternate strand triple-helix. The triple-helix forming oligonucleotides bind in a parallel and antiparallel orientation, respectively, to target sequences on alternate strands of the double helical nucleic acid. The oligonucleotides are useful as diagnostic or therapeutic agents and can incorporate an appropriate moiety in one or more nucleotides in the triple-helix forming oligonucleotide.Type: GrantFiled: December 16, 1993Date of Patent: June 11, 2002Assignee: California Institute of TechnologyInventors: Peter B. Dervan, Peter A. Beal
-
Patent number: 6369116Abstract: Implants and methods are provided for modulating wound healing and controlling infection to improve the success of glaucoma filtration surgery. Formulations of one or more therapeutically active agents and a biodegradable polymer provide a substantially constant rate of release for an extended period of time.Type: GrantFiled: December 23, 1998Date of Patent: April 9, 2002Assignee: Oculex Pharmaceuticals, Inc.Inventors: Vernon Wong, Lin Peng
-
Patent number: 6350731Abstract: Novel peptide analogues of platelet-derived growth factor, for use in inhibiting or stimulating growth and/or chemotaxis of cells, for example, smooth muscle cells, are provided. Also provided are compositions of matter comprising those peptide analogues.Type: GrantFiled: November 2, 1999Date of Patent: February 26, 2002Assignee: Trigen LimitedInventors: Ahmed Mohammed Taki Jehanli, Geeta Patel, Yemisi Olabiran, David Mark Brennand, Vir Vijay Kakkar
-
Patent number: 6303317Abstract: Methods for creating and using polypeptide probes with high affinity for any desirable coiled coil region are described, as well as heterospecific polypeptide probes directed to the coiled coil region of a target polypeptide. Core residue packing rules are provided for selective amino acid pairing and packing in the hydrophobic core of the interhelical interface.Type: GrantFiled: January 28, 1998Date of Patent: October 16, 2001Assignee: The Regents of the University of CaliforniaInventors: Thomas C. Alber, Victoria Allen, Shivani Nautiyal
-
Patent number: 6277570Abstract: Methods and compositions are provided for detecting nucleic acid sequences. Probes comprising a crosslinking agent are combined with a sample which may comprise a target sequence which is complementary to the probe. Hybridization is allowed to occur between complementary sequences. The crosslinking agent is activated. Covalent bonds are formed between the probe and the target sequence if they are hybridized to one another. The crosslinked nucleic acids can then be detected to indicate the presence of the target sequence. Also provided are kits comprising reagents.Type: GrantFiled: September 4, 1998Date of Patent: August 21, 2001Assignee: NaxcorInventors: Michael L. Wood, David Albagli, Reuel B. Van Atta, Peter C. Cheng, Bingfang Huan, Douglas Y. Thien
-
Patent number: 6207159Abstract: Methods for detecting the status of an insulin-dependent diabetes mellitus (IDDM)-associated autoimmune response in a mammal are provided. Specifically, the ratio of the frequency of T helper 1 cells to T helper 2 cells specific for a pancreatic &bgr;-cell associated antigen is indicative of the status of the autoimmune response. The methods may be employed prior to the onset of the clinical symptoms of the disease, thereby allowing identification of those at risk for developing clinical symptoms of IDDM, or subsequent to pancreatic tissue transplantation, for example, to measure the efficacy of treatment directed to enhancing the lifetime of the tissue transplant. Methods for prolonging the survival of tissue transplants are also provided. Specifically, a tissue-associated antigen is administered to the mammal which serves to shift the pathogenic Th1 response associated with pathological immunity toward a protective Th2 response.Type: GrantFiled: July 21, 1998Date of Patent: March 27, 2001Assignee: The Regents of the University of CaliforniaInventors: Daniel L. Kaufman, Jide Tian